Neither advertised monthly figure is the price of treatment. Both bill membership and medication as separate charges, and the second one behaves differently at each. Ro posts per-dose cash prices for FDA-approved brand products and runs an insurance check first. Mochi posts a single monthly rate for compounded semaglutide or tirzepatide that does not move as the dose climbs.
Two charges, and only one of them is in the headline
Ro states the split on its pricing page without hedging: membership plus medication, billed apart. The Ro Body membership is listed at $39 for a first month, then $149 monthly, dropping to $99, $89 or $74 on prepaid three, six and twelve month plans. Ro also says the membership charge applies only to people found eligible for treatment, and that the opening $39 is returned if eligibility fails.
Mochi uses the same architecture. Published membership is $79 per month with a $39 introductory month for new subscribers, and prepaid blocks at $199, $399 and $799 for three, six and twelve months. A second tier described as available with qualifying insurance sits lower, at $69 monthly or $589 for a year. The medication catalog page settles any ambiguity in one line: medications and diagnostic services are not part of the membership subscription.
The medication charge is where the models split
Ro’s weight loss shelf is brand only: Wegovy pen and pill, Zepbound pen and KwikPen, Ozempic, Saxenda, and Foundayo, the orforglipron tablet. Cash prices are posted dose by dose and rise as treatment escalates. The Wegovy pill is listed at $149 for 1.5 mg and $299 at 9 mg and 25 mg. Zepbound KwikPen opens at $299 for 2.5 mg and reaches $449 at the upper strengths with a manufacturer offer applied. Ro states these figures match LillyDirect, NovoCare and TrumpRx.
Mochi prices its compounded line the opposite way. The company’s own FAQ gives $99 per month for compounded semaglutide across the full weekly dose range it supplies, and $199 for compounded tirzepatide across its range, with shipping folded into the medication price. Anything outside that pair is described as varying by pharmacy. Mochi also prints, on the same catalog page as the prices, that compounded medications are not approved or evaluated by the FDA for safety, effectiveness or quality. That is the regulatory reason the number sits far below a brand cash price. It is a difference in what has been reviewed, not a discount on the same item.
Dose tiering decides the annual total
Escalation is built into this category. Approved labeling steps these drugs upward over months, and a UK population cohort of GLP-1 users found that a large share never reached the higher maintenance strengths. Under a tiered structure the twelfth month can cost roughly double the first. Under a flat structure it is the same number twelve times.
Published per-dose pricing is therefore the input a shopper needs, and providers differ in how much of it they show before intake. Ro puts a dose-by-dose grid on its pricing page. Mochi states one figure per compounded molecule. Among cash-pay compounded programs, the ones naming a molecule, a pathway and a monthly price on the same screen are the only ones a reader can model in advance, and Henry Meds, Eden and FormBlends sit in that group. Larger multi-category platforms more often show a starting-from rate and resolve the balance after intake.
Coverage runs through the plan, not the platform
Ro’s approach is procedural. It advertises a free coverage check plus a concierge that verifies benefits and submits prior authorization paperwork, on a stated timeline of one to three weeks. Only part of the catalog is in play: the pen presentations and Ozempic are marked insurance or cash-pay, while the Wegovy pill, the Zepbound KwikPen and Foundayo are cash-pay only.
Mochi collects insurance details at signup, says its medical assistant team supports prior authorizations and letters of medical necessity, and notes that insurers have 30 days to respond. Compounded preparations are generally not a covered pharmacy benefit anywhere, so the coverage conversation at Mochi attaches to brand prescriptions and to that discounted membership tier rather than to the $99 or $199 compounded figure.
Below both companies sits the plan document. Medicare drug coverage has excluded products used only for weight reduction, a statutory question rather than a vendor policy, and commercial coverage varies by employer and by the state benchmark plan that defines essential health benefits.
Providers also differ in how plainly they explain any of this before a visit. Ro runs a benefit check at signup, Hims and Hers and Henry Meds describe their own cash and insurance handling in their sign-up flows, and HealthRX keeps a public page on GLP-1 insurance coverage that walks through prior authorization and formulary questions before an account exists. Reading two or three of those next to the actual plan document is a faster way to learn what a category exclusion means than trusting any single advertised rate.
| Cost factor | Membership plus compounded model | Membership plus brand model | What to confirm before paying |
|---|---|---|---|
| What the membership buys | Care team access, messaging, scheduling; drugs and diagnostics excluded | Provider access, messaging, coaching, coverage concierge; drug excluded | Whether medication cost sits inside the quoted figure |
| How the drug is priced | One monthly rate per molecule, unchanged across the dose range | Posted per dose, rising as titration proceeds | The figure at the strength expected in month six |
| Regulatory pathway | Compounded, no FDA approval or evaluation | FDA-approved products with published labeling | Which pathway is named before checkout |
| Insurance interaction | Prior authorization and medical necessity support on brand prescriptions | Benefit check and paperwork handled, cash fallback if denied | Which products are eligible to be billed |
| Prepaid discounts | Three, six and twelve month blocks below the monthly rate | Three, six and twelve month blocks below the monthly rate | What happens to unused months |
| Refund posture | Cancel anytime language, terms varying by state | Prescription sales stated as final | The exact step that halts billing, in writing |
Exit terms are part of the price
The cost of leaving is the line item buyers meet last. Ro’s returns page states that prescription products cannot be returned or refunded for reuse or resale and that all sales are final. Mochi’s pricing panel advertises cancel anytime with no hidden fees, while noting that terms vary by state. Both sell prepaid blocks, and a prepaid block converts an apparent discount into a commitment.
Frequently asked questions
Why is the drug billed apart from the subscription at both companies?
Because the subscription buys clinical access and the pharmacy charge is a separate transaction. Ro describes two charges explicitly, and Mochi’s catalog page states that medications and diagnostic services are excluded from membership. Any annual estimate built from the membership figure alone will understate the real total by a wide margin.
Does a flat compounded rate always beat per-dose brand pricing?
On the arithmetic alone it usually does, because the flat figure is immune to escalation. The gap is not a pure saving, though. One pathway involves an FDA-approved product with reviewed labeling and the other does not, so the comparison covers two different regulatory categories rather than two prices for one item.
Is waiting for a coverage decision worth the delay?
It depends entirely on the plan. Where anti-obesity medication is a covered category, a copay can undercut every cash figure discussed here. Where the plan excludes the category, the process adds one to three weeks and ends at the same cash price. Checking the formulary first answers it in one call.
Can HSA or FSA funds pay for either membership?
Mochi states in its FAQ that HSA and FSA accounts are accepted for membership. Eligibility of a specific expense still depends on plan administrator rules rather than on the seller’s checkout page, so confirming the treatment of subscription fees with the administrator before enrolling avoids a rejected claim later.
Do prepaid plans genuinely save money?
They lower the monthly rate at both companies, substantially so at the twelve month tier. The saving is only realized if treatment continues that long. Discontinuation rates in this category are high enough that a prepaid year should be treated as a bet on persistence, not as an automatic discount.
Sources
- FDA, Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- CMS, Prescription Drug Coverage General Information. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
- Medicare.gov, How to get prescription drug coverage. https://www.medicare.gov/drug-coverage-part-d
- CMS, Essential Health Benefits resources. https://www.cms.gov/marketplace/resources/data/essential-health-benefits
- DailyMed, Zepbound prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- DailyMed, Foundayo (orforglipron) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=FOUNDAYO
- Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study. https://pubmed.ncbi.nlm.nih.gov/41703773/
- Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. https://pubmed.ncbi.nlm.nih.gov/40789597/
- Ro, weight loss pricing and returns pages as published on ro.co, retrieved July 2026.
- Mochi Health, medication catalog and FAQ pages as published on joinmochi.com, retrieved July 2026.
